Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab with Short-course Radiotherapy and CAPOX for Locally Advanced Rectal Cancer
NCT06760520Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of ivonescimab in rectal cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06760520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06760520.